Review of guidelines on diagnosis and treatment of testosterone deficiency

Testosterone: Action, Deficiency, Substitution, Fourth Edition

Volumn , Issue , 2012, Pages 408-420

  Swerdloff, Ronald S ^a   Wang, Christina C L ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b LA Biomedical Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84931311593     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139003353.019     Document Type: Chapter

References (37)

1. Abrahamsson U, Arver S, Damber JE, Ekstrom U, Giwercman A, Lehtihet M, Link K, Nilsson J, Peeker R, Pousette A, Rosen T, Stroberg P, Willenheimer R (2010) [Testosterone Deficiency Management Programme and Treatment Recommendations.] Svensk Andrologisk Förening, Stockholm. Available at: www.svenskandrologi.se/res/Default/vardprogram.pdf (accessed Feb 22, 2012)
2. American Society for Reproductive Medicine (2006) Treatment of androgen deficiency in the aging male. Fertil Steril 86:S236-S240
3. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW, Felson DT (2000) Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 133:951-963
4. Armoy JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503-510
5. Anawalt BD (2010) Guidelines for testosterone therapy for men: how to avoid a mad (t)ea party by getting personal. J Clin Endocrinol Metab 95:2614-2617
6. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell M, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319
7. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109-122
8. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galvan R (2008) Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male 11:140-145
9. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386-2390
10. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536-2559
11. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT (2010) Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40:189-207
12. Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD (2000) Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 172:220-224
13. Heinemann LA, Saad F, Heinemann K, Thai DM (2004) Can results of the Aging Males’ Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 7:211-218
14. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63:280-293
15. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, Handelsman DJ (2010) Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 73:382-388
16. McLachlan RI (2010) Certainly more guidelines than rules. J Clin Endocrinol Metab 95:2610-2613
17. Meier CT, Nguyen V, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, Meikle AW, Center JR, Eisman JA, Seibel MJ (2008) Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168:47-54
18. Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F, Ross RJ (2006) Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 29:381-391
19. Morales A, Bella AJ, Chun S, Lee J, Assimakopoulos P, Bebb R, Gottesman I, Alarie P, Dugre H, Elliott S (2010) A practical guide to diagnosis, management, and treatment of testosterone deficiency for Canadian Physicians. Can Urol Assoc J 4:269-275
20. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III (2000) Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49:1239-1242
21. Nair KS, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD (2006) DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355:1647-1659
22. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502-1510
23. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ (2002) American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 8:440-456
24. Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, Miner MM, Shabsigh R (2011) The NERI Hypogonadism Screener: psychometric validation in male patients and controls. Clin Endocrinol 74:248-256
25. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ (2009) Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem 46:137-143
26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostatecancer mortality in a randomized European study. N Engl J Med 360:1320-1328
27. Smith KW, Feldman HA, McKinlay JB (2000) Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol 53:703-711
28. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972
29. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, Wu FC (2010) Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, doubleblind, placebo-controlled study. J Clin Endocrinol Metab 95:639-650
30. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R (2008) Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 20:378-387
31. Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM (2006) Testosterone use in men and its effects on bone health. A systematic review and metaanalysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91:2011-2016
32. Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672
33. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS (2004) Longterm testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89:2085-2098
34. Wang C, Nieschlag E, Swerdloff RS, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2009) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 30:1-9
35. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M, Cunningham G (2011) Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34:1669-1675
36. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60:70-98
37. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123-135